Filing Flows › Immucell (ICCC) › Free cash flow
Immucell (ICCC) free cash flow by quarter
Immucell's free cash flow was $2.3M in Q2 2026 (second quarter 2026), -33% from Q1 2026. Over the last 5 quarters it ranged from $310K (Q4 2025) to $3.4M (Q1 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.3M | -33% | +58% |
| Q1 2026 | $3.4M | +995% | +173% |
| Q4 2025 | $310K | -79% | — |
| Q2 2025 | $1.4M | +16% | — |
| Q1 2025 | $1.2M | — | — |
Q2 2026 at a glance
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immucell's free cash flow?
Immucell's free cash flow was $2.3M in Q2 2026 (second quarter 2026), -33% from Q1 2026.
How has Immucell's free cash flow changed?
Over the last 5 quarters it ranged from $310K (Q4 2025) to $3.4M (Q1 2026).